Carter is a molecular biologist with a background in molecular diagnostics, assay development, and genetic engineering of mammalian cells.
He received his M.S. in Clinical Laboratory Sciences from Rush University Medical Center and completed his clinical training at Northwestern Memorial Hospital. He is an ASCP certified molecular biologist and worked as a clinical laboratory scientist in molecular diagnostics at the University of Illinois Medical Center and the Denver VA Medical Center. He received his Ph.D. in Cancer Biology from the University of Nebraska Medical Center then completed his postdoctoral training at UCSF. He worked as a scientist at Guardant Health before joining Octant in 2021.
Outside of the lab, Carter enjoys spending time outdoors with his family and dog.
FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.
Liu C, Barger CJ, Karpf AR. Cancers (Basel). 2021 Jun 19;13(12):3065.
Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer. Barger CJ, Chee L, Albahrani M, Munoz-Trujillo C, Boghean L, Branick C, Odunsi K, Drapkin R, Zou L, Karpf AR. Elife. 2021 Apr 23;10:e55070.
Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer. Barger CJ, Branick C, Chee L, Karpf AR. Cancers (Basel). 2019 Feb 21;11(2):251.
Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR. Oncotarget. 2015 Sep 29;6(29):27613-27.
https://scholar.google.com/citations?user=gHskM6sAAAAJ&hl=en